Precision BioSciences (NASDAQ:DTIL) CEO Sells 20,559 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 20,559 shares of the business’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $3.84, for a total transaction of $78,946.56. Following the sale, the chief executive officer directly owned 243,392 shares in the company, valued at approximately $934,625.28. This represents a 7.79% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Michael Amoroso also recently made the following trade(s):

• On Thursday, January 22nd, Michael Amoroso sold 34,799 shares of Precision BioSciences stock. The shares were sold at an average price of $4.17, for a total transaction of $145,111.83.

Precision BioSciences Price Performance

Shares of DTIL stock traded up $0.07 during midday trading on Thursday, reaching $3.92. 214,558 shares of the company traded hands, compared to its average volume of 225,532. The firm’s 50 day simple moving average is $4.16 and its two-hundred day simple moving average is $5.01. The firm has a market cap of $89.77 million, a PE ratio of -0.47 and a beta of 1.31. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.45 and a quick ratio of 3.45. Precision BioSciences, Inc. has a 1-year low of $3.53 and a 1-year high of $8.82.

Hedge Funds Weigh In On Precision BioSciences

Several institutional investors and hedge funds have recently modified their holdings of DTIL. XTX Topco Ltd acquired a new stake in Precision BioSciences during the fourth quarter worth approximately $149,000. Sphera Funds Management LTD. acquired a new stake in shares of Precision BioSciences during the fourth quarter worth $1,648,000. Quadrature Capital Ltd grew its position in shares of Precision BioSciences by 344.7% in the fourth quarter. Quadrature Capital Ltd now owns 62,129 shares of the company’s stock valued at $258,000 after purchasing an additional 48,158 shares during the period. Occudo Quantitative Strategies LP acquired a new position in Precision BioSciences in the fourth quarter valued at $52,000. Finally, Engineers Gate Manager LP purchased a new position in Precision BioSciences during the fourth quarter worth about $43,000. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Precision BioSciences in a research note on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $60.00.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.